Clinical pharmacology of siRNA therapeutics: current status and future prospects

References

• Zamore PD. RNA interference: big applause for silencing in Stockholm. Cell. 2006;127(6):1083–1086.
   Google Scholar
• Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343–349.
   Google Scholar
• Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 2010;28(11):570–579.
   Google Scholar
• Agrawal N, Dasaradhi P, Mohmmed A, et al. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67(4):657–685.
   Google Scholar
• Lin Y-X, Wang Y, Blake S, et al. RNA nanotechnology-mediated cancer immunotherapy. Theranostics. 2020;10(1):281.
   Google Scholar
• Snead NM, Wu X, Li A, et al. Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants. Nucleic Acids Res. 2013;41(12):6209–6221.
   Google Scholar
• Wood H. FDA approves patisiran to treat hereditary transthyretin amyloidosis. Nat Rev Neurol. 2018;14(10):570.
   Google Scholar
• Scott LJ. Givosiran: first approval. Drugs. 2020;80(3):335–339.
   Google Scholar
• Zhang MM, Bahal R, Rasmussen TP, et al. The growth of siRNA-based therapeutics: updated clinical studies. Biochem Pharmacol. 2021;189:114432.
   Google Scholar
• Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov. 2015;14(12):843–856.
   Google Scholar
• Wartiovaara J, Öfverstedt L-G, Khoshnoodi J, et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest. 2004;114(10):1475–1483.
   Google Scholar
• Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing. Biotechnol Bioeng. 2007;97(4):909–921.
   Google Scholar
• Gao S, Dagnaes-Hansen F, Nielsen EJB, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 2009;17(7):1225–1233.
   Google Scholar
• Kim HJ, Kim A, Miyata K, et al. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev. 2016;104:61–77.
   Google Scholar
• Shegokar R, Al Shaal L, Mishra P. SiRNA delivery: challenges and role of carrier systems. Die Pharmazie- Int J Pharm Sci. 2011;66(5):313–318.
   Google Scholar
• Tai W. Current aspects of siRNA bioconjugate for in vitro and in vivo delivery. Molecules. 2019;24(12):2211.
   Google Scholar
• Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13(19–20):842–855.
   Google Scholar
• Chiu Y-L, Rana TM. siRNA function in RNAi: a chemical modification analysis. Rna. 2003;9(9):1034–1048.
   Google Scholar
• Yu Z, Zhang X, Pei X, et al. Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA. Int J Pharm. 2021;606:120940.
   Google Scholar
• Matsubara M, Honda K, Ozaki K, et al. Synthesis of siRNAs incorporated with cationic peptides R8G7 and R8A7 and the effect of the modifications on siRNA properties. RSC Adv. 2020;10(57):34815–34824.
   Google Scholar
• Sivakumar P, Kim S, Kang HC, et al. Targeted siRNA delivery using aptamer‐siRNA chimeras and aptamer‐conjugated nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(3):e1543.
   Google Scholar
• Aviñó A, Ocampo SM, Lucas R, et al. Synthesis and in vitro inhibition properties of siRNA conjugates carrying glucose and galactose with different presentations. Mol Divers. 2011;15(3):751–757.
   Google Scholar
• Biscans A, Caiazzi J, McHugh N, et al. Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles. Mol Ther. 2021;29(4):1382–1394.
   Google Scholar
• Falato L, Gestin M, Langel Ü. Cell-penetrating peptides delivering siRNAs: an overview. Design Delivery SiRNA Ther. 2021;2283:329–352.
   Google Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–116.
   Google Scholar
• Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS nano. 2011;5(12):9977–9983.
   Google Scholar
• Ceylan S, Bahadori F, Akbas F. Engineering of siRNA loaded PLGA Nano-Particles for highly efficient silencing of GPR87 gene as a target for pancreatic cancer treatment. Pharm Dev Technol. 2020;25(7):855–864.
   Google Scholar
• Saeed RM, Abdullah M, Ahram M, et al. Novel ellipsoid chitosan-phthalate lecithin nanoparticles for siRNA delivery. Front Bioeng Biotechnol. 2021;9:589.
   Google Scholar
• Fakhr E, Zare F, Teimoori-Toolabi L. Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther. 2016;23(4):73–82.
   Google Scholar
• Okamura K, Ishizuka A, Siomi H, et al. Distinct roles for argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev. 2004;18(14):1655–1666.
   Google Scholar
• Alshaer W, Zureigat H, Al Karaki A, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905:174178.
   Google Scholar
• Saw PE, Song E-W. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63(4):485–500.
   Google Scholar
• Neumeier J, Meister G. SiRNA specificity: rNAi mechanisms and strategies to reduce off-target effects. Front Plant Sci. 2021;11(526455):2196.
   Google Scholar
• Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16(9):543–552.
   Google Scholar
• Dana H, Chalbatani GM, Mahmoodzadeh H, et al. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci IJBS. 2017;13(2):48.
   Google Scholar
• Subhan MA, Torchilin V. siRNA based drug design, quality, delivery and clinical translation. Nanomedicine. 2020;29:102239.
   Google Scholar
• Baas J, Senninger N, Elser H. The reticuloendothelial system. An overview of function, pathology and recent methods of measurement. Z Gastroenterol. 1994;32(2):117–123.
   Google Scholar
• Caillaud M, El Madani M, Massaad-Massade L. Small interfering RNA from the lab discovery to patients’ recovery. J Control Release. 2020;321:616–628.
   Google Scholar
• Juliano R, Bauman J, Kang H, et al. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm. 2009;6(3):686–695.
   Google Scholar
• S-D L, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochimi Biophys Acta (BBA) Biomembr. 2009;1788(10):2259–2266.
   Google Scholar
• Mainini F, Eccles MR. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules. 2020;25(11):2692.
   Google Scholar
• Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7:5577.
   Google Scholar
• Subhan MA, Attia SA, Torchilin VP. Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sci. 2021;274:119337.
   Google Scholar
• Van de Water FM, Boerman OC, Wouterse AC, et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos. 2006;34(8):1393–1397.
   Google Scholar
• Huang Y, Hong J, Zheng S, et al. Elimination pathways of systemically delivered siRNA. Mol Ther. 2011;19(2):381–385.
   Google Scholar
• Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(8):1183–1189.
   Google Scholar
• El-Andaloussi S, Lee Y, Lakhal-Littleton S, et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc. 2012;7(12):2112–2126.
   Google Scholar
• Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides. 2009;19(2):89–102.
   Google Scholar
• Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31(11):2705–2716.
   Google Scholar
• Ku SH, Jo SD, Lee YK, et al. Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev. 2016;104:16–28.
   Google Scholar
• Deleavey GF, Watts JK, Damha MJ. Chemical modification of siRNA. Curr Protoc Nucleic Acid Chem. 2009;39(1):16.3. 1–16.3. 22.
   Google Scholar
• Sanghvi YS. A status update of modified oligonucleotides for chemotherapeutics applications. Current protocols in nucleic acid chemistry. Curr Protoc Nucleic Acid Chem. 2011;46(1):4.1. 1–4.1. 22.
   Google Scholar
• Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005;41(6):1349–1356.
   Google Scholar
• Wang H, Ghosh A, Baigude H, et al. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem. 2008;283(23):15845–15852.
   Google Scholar
• Sugo T, Terada M, Oikawa T, et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control Release. 2016;237:1–13.
   Google Scholar
• Kortylewski M, Swiderski P, Herrmann A, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol. 2009;27(10):925–932.
   Google Scholar
• Larsen MT, Kuhlmann M, Hvam ML, et al. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. 2016;4(1):1–12.
   Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25(10):1149–1157.
   Google Scholar
• Green M, Ishino M, Loewenstein PM. Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell. 1989;58(1):215–223.
   Google Scholar
• Pooga M, Hällbrink M, Zorko M, et al. Cell penetration by transportan. FASEB J. 1998;12(1):67–77.
   Google Scholar
• Dohmen C, Fröhlich T, Lächelt U, et al. Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing. Mol Ther Nucleic Acids. 2012;1:e7.
   Google Scholar
• Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958–16961.
   Google Scholar
• Iversen F, Yang C, Dagnæs-Hansen F, et al. Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics. 2013;3(3):201.
   Google Scholar
• Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Nat Acad Sci. 2007;104(32):12982–12987.
   Google Scholar
• Lee C-W, SC-S H, Yen F-L, et al. Magnolol nanoparticles exhibit improved water solubility and suppress TNF-α-induced VCAM-1 expression in endothelial cells. J Biomed Nanotechnol. 2017;13(3):255–268.
   Google Scholar
• Haggag YA, Yasser M, Tambuwala MM, et al. Repurposing of Guanabenz acetate by encapsulation into long-circulating nanopolymersomes for treatment of triple-negative breast cancer. Int J Pharm. 2021;600:120532.
   Google Scholar
• Tchoryk A, Taresco V, Argent RH, et al. Penetration and uptake of nanoparticles in 3D tumor spheroids. Bioconjug Chem. 2019;30(5):1371–1384.
   Google Scholar
• Abdelkader DH, Abosalha AK, Khattab MA, et al. A novel sustained anti-inflammatory effect of atorvastatin—calcium PLGA nanoparticles: in vitro optimization and in vivo. Pharmaceutics. 2021;13(10):1658.
   Google Scholar
• Zewail MB, El-Gizawy SA, Osman MA, et al. Preparation and In vitro characterization of a novel self-nano emulsifying drug delivery system for a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide. J Drug Delivery Sci Technol. 2021;61:102320.
   Google Scholar
• Gunasekaran T, Haile T, Nigusse T, et al. Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine. Asian Pac J Tropical Biomedicine. 2014;4:S1–S7.
   Google Scholar
• Haggag Y, Abu Ras B, El-Tanani Y, et al. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opin Drug Deliv. 2020;17(11):1655–1669.
   Google Scholar
• Lü J-M, Wang X, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325–341.
   Google Scholar
• Pantazis P, Dimas K, Wyche JH, et al. Nanoparticles in Biology and Medicine. In: Preparation of siRNA-encapsulated PLGA nanoparticles for sustained release of siRNA and evaluation of encapsulation efficiency. New York City, U.S: Springer, 2012. p. 311–319.
   Google Scholar
• Risnayanti C, Jang Y-S, Lee J, et al. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Sci Rep. 2018;8(1):1–12.
   Google Scholar
• Zhang H-L, S-h W, Tao Y, et al. Preparation and characterization of water-soluble chitosan nanoparticles as protein delivery system. J Nanomater. 2010;2010:1–5.
   Google Scholar
• Mohammed MA, Syeda J, Wasan KM, et al. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics. 2017;9(4):53.
   Google Scholar
• Lin Q, Jiang G, Tong K. Dendrimers in drug-delivery applications. Des Monomers Polym. 2010;13(4):301–324.
   Google Scholar
• Biswas S, Torchilin VP. Dendrimers for siRNA delivery. Pharmaceuticals. 2013;6(2):161–183.
   Google Scholar
• Chen J, Ellert-Miklaszewska A, Garofalo S, et al. Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells. Nat Protoc. 2021;16(1):327–351.
   Google Scholar
• Kwak SY, Lee S, Han HD, et al. PLGA nanoparticles codelivering siRNAs against programmed cell death protein-1 and its ligand gene for suppression of colon tumor growth. Mol Pharm. 2019;16(12):4940–4953.
   Google Scholar
• Van Woensel M, Wauthoz N, Rosière R, et al. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release. 2016;227:71–81.
   Google Scholar
• Jain R, Dandekar P, Loretz B, et al. Dimethylaminoethyl methacrylate copolymer-siRNA nanoparticles for silencing a therapeutically relevant gene in macrophages. MedChemComm. 2015;6(4):691–701.
   Google Scholar
• Dong Y, Yu T, Ding L, et al. A dual targeting dendrimer-mediated siRNA delivery system for effective gene silencing in cancer therapy. J Am Chem Soc. 2018;140(47):16264–16274.
   Google Scholar
• Nisini R, Poerio N, Mariotti S, et al. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol. 2018;9:155.
   Google Scholar
• Olusanya TO, Haj Ahmad RR, Ibegbu DM, et al. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018;23(4):907.
   Google Scholar
• Ge X, Wei M, He S, et al. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics. 2019;11(2):55.
   Google Scholar
• Obeid MA, Alyamani H, Amawi H, et al. siRNA delivery to melanoma cells with cationic niosomes. Melanoma: Springer; 2021. p. 621–634.
   Google Scholar
• Guo S, Li K, Hu B, et al. Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment. In: Exploration. New Jersey, U.S: Wiley Online Library; 2021. p. 35–49.
   Google Scholar
• Ud Din F, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;12:7291.
   Google Scholar
• Chis AA, Dobrea C, Morgovan C, et al. Applications and limitations of dendrimers in biomedicine. Molecules. 2020;25(17):3982.
   Google Scholar
• Bedi D, Musacchio T, Fagbohun OA, et al. Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. Nanomedicine. 2011;7(3):315–323.
   Google Scholar
• Song L, Fan Z, Jun N, et al. Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma. Oncotarget. 2016;7(51):85163.
   Google Scholar
• Hanafy MS, Hufnagel S, Trementozzi AN, et al. PD-1 siRNA-encapsulated solid lipid nanoparticles downregulate PD-1 expression by macrophages and inhibit tumor growth. AAPS PharmSciTech. 2021;22(2):1–8.
   Google Scholar
• Moghimi SM, Symonds P, Murray JC, et al. A two-stage poly (ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther. 2005;11(6):990–995.
   Google Scholar
• Ballarin-Gonzalez B, Howard KA. Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions. Adv Drug Deliv Rev. 2012;64(15):1717–1729.
   Google Scholar
• Zheng M, Jiang T, Yang W, et al. The siRNAsome: a cation‐free and versatile nanostructure for siRNA and drug co‐delivery. Angew Chem. 2019;58(15):4938–4942.
   Google Scholar
• Jensen SA, Day ES, Ko CH, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013;5(209):209ra152–209ra152.
   Google Scholar
• Jiang T, Qiao Y, Ruan W, et al. Cation‐free siRNA micelles as effective drug delivery platform and potent RNAi nanomedicines for glioblastoma therapy. Adv Mater. 2021;33(45):2104779.
   Google Scholar
• Kumthekar P, Ko CH, Paunesku T, et al. A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021;13(584):eabb3945.
   Google Scholar
• Luo J, Höhn M, Reinhard S, et al. IL4‐receptor‐targeted dual antitumoral apoptotic peptide—siRNA conjugate lipoplexes. Adv Funct Mater. 2019;29(25):1900697.
   Google Scholar
• Khanali J, Azangou-khyavy M, Asaadi Y, et al. Nucleic-Acid Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs. Front Microbiol. 2021;12:758948.
   Google Scholar
• Liu X, Rocchi P, Fq Q, et al. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem. 2009;4(8):1302–1310.
   Google Scholar
• Khabazian E, Vakhshiteh F, Norouzi P, et al. Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma cancer cells. J Drug Target. 2022;30:522–533.
   Google Scholar
• Oner E, Kotmakci M, Baird A-M, et al. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small‐molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. J Nanobiotechnology. 2021;19(1):1–20.
   Google Scholar
• Gonzalez-Duarte A, Adams D, Tournev I, et al. HELIOS-A: results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. J Am Coll Cardiol. 2022;79(9_Supplement):302.
   Google Scholar
• Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in people with hemophilia a or B without inhibitors (ATLAS-A/B). Blood. 2021;138:LBA–3.
   Google Scholar
• Hayreh SS, MB Z. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graef‘s Archive for clinical and experimental opthalmology. JGsafc, ophthalmology e. 2008;246(7):1029–1046.
   Google Scholar
• Ruz V, Gonzalez V, Bleau A-M, et al. Clinical results of tivanisiran, a siRNA for the treatment of dry eye disease. Investig. Ophthalmol. Vis. Sci. 2019;60(9):6738.
   Google Scholar
• Waddington-Cruz M, Schmidt H, Botteman MF, et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis. 2019;14(1):1–7.
   Google Scholar
• Vita G, Vita GL, Musumeci O, et al. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. Neurol Sci. 2019;40(4):671–681.
   Google Scholar
• Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411–423.
   Google Scholar
• Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–1300.
   Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   Google Scholar
• Kulkarni JA, Witzigmann D, Leung J, et al. Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. Nanoscale. 2019;11(18):9023–9031.
   Google Scholar
• Wahlich J, Desai A, Greco F, et al. Nanomedicines for the delivery of biologics. Basel, Switzerland: Multidisciplinary Digital Publishing Institute; 2019.
   Google Scholar
• Setten RL, Rossi JJ, S-p H. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–446.
   Google Scholar
• Urits I, Swanson D, Swett MC, et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9(2):301–315.
   Google Scholar
• Weng Y, Xiao H, Zhang J, et al. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37(5):801–825.
   Google Scholar
• ONPATTRO full prescribing information by FDA. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf
   Google Scholar
• Wang B, Rudnick S, Cengia B, et al. Acute hepatic porphyrias: review and recent progress. Hepatol Commun. 2019;3(2):193–206.
   Google Scholar
• Bissell DM. The porphyrias. Amsterdam, Netherlands: Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease; 2015.
   Google Scholar
• Bissell DM, Lai JC, Meister RK, et al. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med. 2015;128(3):313–317.
   Google Scholar
• Syed YY. Givosiran: a review in acute hepatic porphyria. Drugs. 2021;81(7):841–848.
   Google Scholar
• Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289–2301.
   Google Scholar
• GIVLAARI full prescribing informations by FDA 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf
   Google Scholar
• Chan A, Liebow A, Yasuda M, et al. Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol Ther Nucleic Acids. 2015;4:e263.
   Google Scholar
• Salido EC, Li XM, Lu Y, et al. Alanine–glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Nat Acad Sci. 2006;103(48):18249–18254.
   Google Scholar
• Danpure C, Jennings P. Peroxisomal alanine: glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett. 1986;201(1):20–34.
   Google Scholar
• Lieske JC, Monico CG, Holmes WS, et al. International registry for primary hyperoxaluria. Am J Nephrol. 2005;25(3):290–296.
   Google Scholar
• Mandrile G, Van Woerden CS, Berchialla P, et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014;86(6):1197–1204.
   Google Scholar
• Leflot M, Krzesinski J-M, Collard L, et al. Type 1 primary hyperoxaluria: from childhood to adult, how to manage adequately medical therapy compliance? Nephrol Ther. 2017;14(3):148–152.
   Google Scholar
• Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369(7):649–658.
   Google Scholar
• Hoppe B. Evidence of true genotype–phenotype correlation in primary hyperoxaluria type 1. Kidney Int. 2010;77(5):383–385.
   Google Scholar
• Marangella M, Petrarulo M, Vitale C, et al. Plasma and urine glycolate assays for differentiating the hyperoxaluria syndromes. J Urol. 1992;148(3):986–989.
   Google Scholar
• Petrarulo M, Vitale C, Facchini P, et al. Biochemical approach to diagnosis and differentiation of primary hyperoxalurias: an update. J Nephrol. 1998;11:23–28.
   Google Scholar
• OXLUMO full prescribing informations by FDA 2020. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf)
   Google Scholar
• Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216–1226.
   Google Scholar
• Sheridan C. PCSK9-gene-silencing, cholesterol-lowering drug impresses. Nat Biotechnol. 2019;37(12):1385–1388.
   Google Scholar
• Dyrbuś K, Gąsior M, Penson P, et al. Inclisiran—New hope in the management of lipid disorders? J Clin Lipidol. 2020;14(1):16–27.
   Google Scholar
• Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4–7.
   Google Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51.
   Google Scholar
• LEQVIO® (inclisiran) full prescribing information by FDA 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf
   Google Scholar
• Lozada-Delgado EL, Grafals-Ruiz N, Vivas-Mejía PE. RNA interference for glioblastoma therapy: innovation ladder from the bench to clinical trials. Life Sci. 2017;188:26–36.
   Google Scholar
• Zahir-Jouzdani F, Mottaghitalab F, Dinarvand M, et al. siRNA delivery for treatment of degenerative diseases, new hopes and challenges. J Drug Delivery Sci Technol. 2018;45:428–441.
   Google Scholar
• Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–726.
   Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature. 2021;593(7857):130–135.
   Google Scholar
• Idris A, Davis A, Supramaniam A, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021;29(7):2219–2226.
   Google Scholar